Stanley C. Jordan, MD, FASN, FAST - Visualizing Progress in the Treatment of Chronic Active Antibody-Mediated Rejection: A Closer Look at the Clinical Potential of Targeting IL-6 to Improve Outcomes in the Kidney Transplant Setting

Go online to PeerView.com/RBD860 to view the activity, download
slides and practice aids, and complete the post-test to earn
credit. In this animated video activity, Dr. Stanley C. Jordan
discusses the rationale for targeting IL-6 in chronic active
antibody-mediated rejection, as well as the use of anti–IL-6 agents
for the treatment of chronic active antibody-mediated rejection in
the kidney transplant setting. Upon completion of this activity,
participants should be better able to: Utilize the Banff
classification to characterize the nature and extent of kidney
transplant rejection in order to guide treatment; Discuss the
rationale for targeting IL-6 as a therapeutic approach to chronic
active antibody-mediated rejection in kidney transplant recipients;
and Evaluate the efficacy, safety, and clinical potential of
anti–IL-6 agents currently in development for the treatment of
chronic active antibody-mediated rejection in the kidney transplant
setting